Clinical Trials

540 enrolled

Phase 3 Not yet recruiting

HER2-positive Breast Cancer

NCT07432178 2026-02-25

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

2,288 enrolled

Breast Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT07423611 2026-02-20

RACE

388 enrolled

Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

85 enrolled

Triple Negative Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT07402473 2026-02-11

EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer

50 enrolled

HER2-positive Early-stage Breast Cancer

NCT07386938 2026-02-04

A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

246 enrolled

Breast Neoplasms

NCT07196774 2026-01-30

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

740 enrolled

Early-stage or Locally Advanced HER2-positive Breast Cancer

NCT04095689 2026-01-23

INTEGRAL

Phase 2 Terminated

8 enrolled 10 charts

BreastGenitourinaryHead & NeckThoracic

Triple Negative Breast Neoplasms

NCT07358806 2026-01-22

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Phase 1 Recruiting

51 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Phase 2 Active not recruiting

53 enrolled 13 charts

Breast Neoplasms

NCT05296798 2026-01-16

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

922 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

140 enrolled

Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

190 enrolled 12 charts

Breast Neoplasms

NCT05256745 2025-12-24

RAGE

Phase 1/2 Recruiting

48 enrolled

Cancer Related Cognitive Decline

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

144 enrolled

Breast Neoplasms

NCT03595059 2025-12-10

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Phase 1 Completed

168 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Small Cell Lung Carcinoma

NCT02688803 2025-12-04

OTT15-04

Phase 4 Terminated

2 enrolled 4 charts

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

188 enrolled

Breast Neoplasms

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT04514419 2025-11-21

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

408 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

140 enrolled

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT04329065 2025-11-06

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

25 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT05929768 2025-11-05

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

2,400 enrolled

Phase 1 Active not recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT03218826 2025-10-30

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

23 enrolled 15 charts

BreastGenitourinary

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT07220135 2025-10-23

NeoTHERa

100 enrolled

Breast Neoplasms

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT06042569 2025-10-09

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

174 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT05645380 2025-10-07

NeoTRACT

139 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07017673 2025-10-06

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

34 enrolled

Triple Negative Breast Neoplasms

NCT03264547 2025-09-29

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

446 enrolled

Breast Neoplasms

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Phase 1/2 Recruiting

10 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT07043725 2025-09-23

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

544 enrolled

HER2-positive Breast Cancer

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT02514681 2025-09-10

PRECIOUS

226 enrolled

Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled